Select country set
Menu Shopping cart 0,00 Search
Manufactured by BioVendor

Heart FABP (FABP3) Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:FABP3, Fatty acid-binding protein 3, H-FABP, Mammary-derived growth inhibitor, MDGI, Muscle fatty acid-binding protein, M-FABP, FABP11
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

Availability on Request RD192247200R 96 wells (1 kit)
PubMed Product Details
Technical Data


Sandwich ELISA, Biotin-labelled antibody


Serum, Urine, Cerebrospinal fluid, Bronchoalveolar lavage, Amniotic fluid, Plasma

Sample Requirements

50 µl/well


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

20 – 1280 pg/ml

Limit of Detection

5.6 pg/ml

Intra-assay (Within-Run)

n = 8, CV = 3.6%

Inter-assay (Run-to-Run)

n = 6, CV = 5,4%

Spiking Recovery


Dilution Linearity




  • The total assay time is less than 3.5 hours
  • The kit measures H-FABP in human serum, plasma (EDTA, citrate, heparin), urine, cerebrospinal fluid (CSF), bronchoalveolar lavage fluid (BALF) and amniotic fluid
  • Assay format is 96 wells
  • Standard is recombinant protein based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Cardiovascular disease, Energy metabolism and body weight regulation, Renal disease


Heart fatty acid binding protein (H-FABP) or FABP3, belongs to the fatty acid binding proteins (FABP) family being characterized by relative tissue specificity. H-FABP is one of the most abundant proteins in the cardio myocytes comprising 5-15% of the total cytosolic protein pool. Except its basic role to transport fatty acids towards the mitochondria for β-oxidation, H-FABP protects against free radical accumulation during myocardial ischemia and influences signal transduction pathways for gene expression via peroxisome proliferator-activated receptor. H-FABP is not totally heart specific and also has been found in skeletal muscle in concentration 10-fold lower than that in heart muscle and in low concentrations in kidney, liver, small intestine, brain, lactating mammary glands, placenta, adipose tissue, adrenal glands and stomach. Under normal conditions H-FABP is presented in plasma at very low concentration. During ischemia, H-FABP leaks out of myocardial tissue and the concentration increases in the blood within 2 hours and is reported to peak at about 4-6 hours and return to normal baseline value in 20 hours. H-FABP is a valuable marker of acute coronary syndromes, heart failure, pulmonary embolism, renal, brain and skeletal muscle injury and its utility increases when is evaluated in combination with other biochemical markers. Thanks to its small size, H-FABP can quickly pass through the kidney to urine, which also gives an opportunity to measure it noninvasively in urine.

Summary References (12)

References to Heart Fatty Acid Binding Protein

  • Pelsers MMAL, Hanhoff T, Van der Voort D, Arts B, Peters M, Ponds R, Honig A, Rudzinski W, Spener F, de Kruijk JR, Twijnstra A, Hermens W, Menheere PPCA, Glatz JFC: Brain and heart type fatty acid-binding proteins in the brain: Tissue distribution and clinical utility. Clin Chem 2004, 50(9):1568-1575
  • Cavus U, Coskum F, Yavuz B, Ciftci O, Sahiner L, Aksoy H, Deniz A, Ozakin E, Aytemir K, Tokgozoglu L, Kabakci G: Heart-type, fatty-acid binding protein can be a diagnostic marker in acute coronary syndrome. J Nat Med Ass 2006, 98(7):1067-1070
  • Storch J, McDermott L: Structural and functional analysis of fatty acid-binding proteins. J Lipid Res 2009, S126-S131
  • Hussain T, Shu LY, Sosorburam T: Importance of cardiac FABP as diagnostic marker of ischaemic heart injury in conjuction with chronic liver disease: A cohort study. Australian Medical J 2010, 3(11):691-694
  • Li Ch, Li J, Liang X, Li X, Cui J, Yang Z, Guo Q, Cao K, Huang J: Point-of-care test of heart-type fatty acid-binding protein for the diagnosis of early acute myocardial infarction. Acta Pharmacologica Sinica 2010, 31:307-312
  • Gururajan P, Gurumurthy P, Nayar P, Rao GSN, Babu S, Cherian KM: Heart fatty acid binding protein (H-FABP) as a diagnostic biomarker in patients with acute coronary syndrome. Heart, Lung and Circulation 2010, 19:660-664
  • Karbek B, Ozbek M, Bozkurt NC, Ginis Z, Gungunes A, Unsal IO, Cakal E, Delibasi T: Heart-type fatty acid binding protein (H-FABP): relationship with arterial intima-media thickness and role as diagnostic marker for atherosclerosis in patients with impaired glucose metabolism. Cardiovasc Diabet 2011, 10:37
  • Elmadbouh I, Mahfouz, Bayomy N, Faried W, Ghanayem N: The value of human heart-type fatty acid binding protein in diagnosis of patients with acute chest pain. The Egypt Heart J 2012, 64:179-184
  • Erenler AK, Yardan T, Duran L, Baydin A: Usefulness of heart-type fatty acid binding protein in the emergency department. J Pak Med Assoc 2013, 63(9):1176-1181
  • Willemsen RTA, Buntinx F, Winkens B, Glatz JF, Dinant GJ, RAPIDA-study team): The value of signs, symptoms and plasma heart-type fatty acid-binding protein (H-FABP) in evaluating patients presenting with symptoms possibly matching acute coronary syndrome: background and methods of a diagnostic study in primary care. BMC Family Pract 2014, 15:203
  • Pyati AK, devaranavadagi BB, Sajjannar SL, Nikam SV, Shannaway M, Sudharani: Heart-type fatty acid binding protein: a better cardiac biomarker than CK-MB and myoglobin in the early diagnosis of acute myocardial infarction. J Clin Diagn Research 2015, 9(10):BC08-BC11
  • Hoffmann U, Espeter F, Weis C, Ahmad-Nejad P, Lang S, Brueckmann M, Akin I, Neumaier M, Borggrefe M, Behnes M: Ischemic heart-type fatty acid binding protein (hFABP) in acute
Related Products Docs